News
-
-
PRESS RELEASE
Capital B confirme l'acquisition de 6 BTC pour 0,6 MEUR, la détention d'un total de 2 818 BTC, et un 'BTC Yield' de 1 657,7% depuis le début de l'année
Capital B finalise une augmentation de capital avec TOBAM, acquérant 6 BTC pour 0,6 M€. Suspension temporaire du contrat. Détention de 2 818 BTC pour 262,7 M€. Stratégie d'accumulation renforcée -
PRESS RELEASE
Capital B confirms the acquisition of 6 BTC for EUR0.6 million, the holding of a total of 2,818 BTC, and a BTC Yield of 1,657.7% YTD
Capital B confirms final completion of a €0.6 million capital increase at €1.18 per share, acquiring 6 BTC. Temporary suspension of capital program with TOBAM. Group holds 2,818 BTC valued at €262.7 million -
-
-
PRESS RELEASE
E+S Rück anticipates a stable market environment in Germany for 2026 and continued growth in demand for reinsurance protection
E+S Rück anticipates stable market environment in Germany for 2026, with continued growth in demand for reinsurance protection. Full range of innovative solutions offered -
-
PRESS RELEASE
2025 Q3 Sales: Revenue of €6.1 Billion, Stable on an Organic Basis. Strong Financial Discipline. 2025 Guidance Confirmed
FORVIA reports stable organic sales of €6.1 billion in Q3 2025, strong financial discipline, and confirms 2025 guidance. Focus on efficiency measures and debt profile improvement -
PRESS RELEASE
Press Release: Sanofi’s high-dose influenza vaccine demonstrates superior protection for older adults against hospitalization vs standard-dose
Sanofi's high-dose influenza vaccine Efluelda/Fluzone High-Dose shows superior protection for older adults by reducing hospitalizations. FLUNITY-HD study details robust evidence published in The Lancet -
PRESS RELEASE
Communiqué de presse : Le vaccin antigrippal à haute dose de Sanofi démontre une protection supérieure contre les hospitalisations chez les séniors par rapport aux vaccins à dose standard
Le vaccin antigrippal à haute dose de Sanofi démontre une protection supérieure contre les hospitalisations chez les seniors par rapport aux vaccins à dose standard